Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Escitalopram
Drug ID BADD_D00809
Description Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram].[A185420] It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class.[A185726] Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.[A185825,A185726,A185822]
Indications and Usage Escitalopram is indicated for both acute and maintenance treatment of major depressive disorder (MDD) and for the acute treatment of generalized anxiety disorder (GAD).[L8513] It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.[L8516]
Marketing Status approved
ATC Code N06AB10
DrugBank ID DB01175
KEGG ID D07913
MeSH ID D000089983
PubChem ID 146570
TTD Drug ID D08RBC
NDC Product Code 80425-0320; 50090-4915; 51655-284; 53002-1431; 67296-1200; 0456-2010; 0456-2020; 69097-848; 70518-1785; 71335-1030; 0615-8366; 42708-163; 45865-699; 55700-847; 69844-079; 72189-424; 72189-451; 16729-168; 43547-281; 43547-282; 61919-652; 63187-281; 68001-456; 68071-5248; 68788-7461; 69844-077; 70934-630; 68001-454; 68071-2035; 68645-520; 68788-7510; 69844-078; 70934-957; 71205-344; 71610-425; 71610-534; 72189-449; 16571-755; 16729-170; 50090-2196; 51655-236; 53002-2438; 60760-393; 68788-7912; 70518-2317; 70771-1145; 71335-1002; 71335-1187; 71335-1307; 16571-757; 51655-766; 54838-551; 70518-2430; 70771-1147; 50090-4363; 50090-5312; 50090-6534; 51655-116; 51655-149; 69097-847; 69097-849; 70518-1876; 71205-325; 76282-250; 76282-251; 42708-155; 50090-1930; 70518-2472; 70518-3151; 70771-1146; 82982-030; 43547-280; 50090-6190; 51655-277; 55700-818; 63187-217; 67296-1597; 68001-455; 68645-519; 0456-2005; 70518-1805; 70518-2597; 71335-1571; 72189-438; 0615-8365; 72789-194; 76282-249; 16571-756; 33342-053; 60760-170; 65162-705; 71205-782; 71335-1241; 71335-2058; 0615-8348; 16729-169; 43063-661
UNII 4O4S742ANY
Synonyms Escitalopram | Escitalopram Oxalate | Lexapro
Chemical Information
Molecular Formula C20H21FN2O
CAS Registry Number 128196-01-0
SMILES CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Plantar fasciitis15.03.03.002--Not Available
Platelet count decreased13.01.04.001--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pollakiuria20.02.02.0070.000057%
Polydipsia14.05.02.001; 05.03.03.0020.000042%Not Available
Polyuria20.02.03.0020.000028%Not Available
Postpartum haemorrhage24.07.03.003; 18.06.01.0010.000057%Not Available
Pre-eclampsia24.08.07.002; 20.01.08.002; 18.02.03.0020.000028%Not Available
Pregnancy18.08.02.0040.000324%Not Available
Pregnancy test positive13.10.05.012--Not Available
Premature baby18.04.02.0010.000218%Not Available
Premature ejaculation21.03.01.008; 19.08.01.0020.000019%Not Available
Premenstrual syndrome17.14.01.019; 21.01.01.007; 19.04.02.0090.000028%Not Available
Pressure of speech19.19.03.0060.000028%Not Available
Presyncope24.06.02.010; 02.11.04.013; 17.02.05.0090.000114%
Priapism24.04.12.007; 21.03.01.0050.000057%Not Available
Productive cough22.02.03.005--
Prostatic disorder21.04.01.001--Not Available
Prothrombin level decreased13.01.02.010--Not Available
Pruritus23.03.12.001--
Pruritus genital23.03.12.008; 21.10.01.002--Not Available
Psoriasis23.03.14.002; 10.02.01.036--Not Available
Psychomotor hyperactivity19.11.02.003; 17.01.02.0110.000161%Not Available
Psychomotor retardation19.15.02.0020.000152%Not Available
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary hypertension24.08.03.002; 22.06.01.0010.000057%
Pulmonary infarction24.04.09.001; 22.06.02.0020.000019%Not Available
Purpura23.06.01.004; 24.07.06.005; 01.01.04.003--
Pyelonephritis20.01.09.001; 11.01.14.002--Not Available
Pyelonephritis acute20.01.09.002; 11.01.14.003--Not Available
The 20th Page    First    Pre   20 21 22 23 24    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene